BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/340/0.1/20.12.24

BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/340/0.1/20.12.24 Share Price

DE000VD3YF07

Market Closed - Boerse Frankfurt Warrants 18:53:52 27/06/2024 BST
0.21 ^EUR	-8.70%

Current month	-61.82%
1 month	-44.74%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/340/0.1/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT

More news

Quotes 5-day view

Date	Price	Change
27/06/24	0.21	-8.70%
26/06/24	0.23	0.00%
25/06/24	0.23	0.00%
24/06/24	0.23	-14.81%
21/06/24	0.27	+8.00%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 06:53 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD3YF0
ISIN	DE000VD3YF07
Date issued	11/04/2024
Strike	340 $
Maturity	20/12/2024 (176 Days)
Parity	10 : 1
Emission price	1.22 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.55 €
Lowest since issue	0.157 €
Spread	0.04 €
Spread %	13.79%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company